Document is current
Any future updates will be listed below
-
Authors
Kamihara, Junne
Fisher, Lauren
Schienda, Jaclyn
Vanderwall, Rebecca
Snir, Moran
Snir, Guy
Simmons, Emilie
Khalaj, Andrew
Goler, Evan
Hamilton, Kayla V.
Porter, Christopher C.
Pencheva, Bojana
Schiffman, Joshua D.
Maese, Luke D.
Kohlmann, Wendy
Henderson, Tara O.
Garber, Judy E.
Diller, Lisa R.
Desai, Ami V.
Savage, Sarah
Klosky, James L.
Rana, Huma Q.
Mack, Jennifer W.
-
Funding
Funding for this research was provided by:
National Institutes of Health (1UO1CA243688-01)
National Institutes of Health (1UO1CA243688-01)
National Institutes of Health (1UO1CA243688-01)
National Institutes of Health (1UO1CA243688-01)
National Institutes of Health (1UO1CA243688-01)
National Institutes of Health (1UO1CA243688-01)
National Institutes of Health (1UO1CA243688-01)
National Institutes of Health (1UO1CA243688-01)
National Institutes of Health (1UO1CA243688-01)
National Institutes of Health (1UO1CA243688-01)
National Institutes of Health (1UO1CA243688-01)
National Institutes of Health (1UO1CA243688-01)
National Institutes of Health (1UO1CA243688-01)
National Institutes of Health (1UO1CA243688-01)
National Institutes of Health (1UO1CA243688-01)
National Institutes of Health (1UO1CA243688-01)
National Institutes of Health (1UO1CA243688-01)
National Institutes of Health (1UO1CA243688-01)
National Institutes of Health (1UO1CA243688-01)
National Institutes of Health (1UO1CA243688-01)
- License Information
-
More Information
Article History
Received: 15 August 2025
Accepted: 14 December 2025
First Online: 23 January 2026
Declarations
:
: AVD reports advisory board/consultancy fees from Y-mAbs Therapeutics, Glaxo Smith Kline, and Recordati and stock ownership in Pfizer and Viatris. JDS is shareholder and employed by Peel Therapeutics, Inc. unrelated to this work. JK’s spouse has received consulting fees from ROME Therapeutics, Sonata Therapeutics, Leica Biosystems Imaging, PanTher Therapeutics, 65 Therapeutics, and abrdn; is a founder and has equity in ROME Therapeutics, PanTher Therapeutics and TellBio, Inc.; is on the advisory board with equity for ImproveBio, Inc. and 65 Therapeutics; has received honorariums from Astellas, AstraZeneca, Moderna, and Ikena Oncology; receives research support from ACD-Biotechne, AVA LifeScience GmbH, Incyte Pharmaceuticals, Sanofi, and Astellas. None of the above are related to this work
